Product Description
for neutropenia prophylaxis in breast cancer patients receiving doxorubicin and cyclophosphamide myelosuppressive chemotherapy
Mechanisms of Action: TLR2 Agonist
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioLab 612
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Neutropenia|Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02778763 |
BL-612-BC1 | P2 |
Completed |
Breast Cancer|Neutropenia |
2016-07-01 |
2019-03-20 |
Recent News Events
Date |
Type |
Title |
|---|